RayBiotech

RayBiotech

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

RayBiotech is a privately-held provider of protein detection and analysis solutions, operating in the life sciences tools and diagnostics sectors. The company has established a strong position in the research market with its proprietary antibody array and assay platforms, which facilitate high-throughput, multiplexed protein analysis. While primarily a tools and kits supplier, its technology supports critical workflows in drug discovery, translational research, and diagnostic development. RayBiotech's business model is based on product sales and services, generating revenue from a global customer base.

DiagnosticsAntibodies

Technology Platform

Proprietary antibody-based microarray and multiplex immunoassay platforms for high-throughput protein detection and analysis, including antibody arrays and ELISA kits.

Opportunities

The growing demand for multiplexed protein analysis in biomarker discovery and systems biology research presents a steady market.
Translating its research-use technology into validated clinical diagnostic kits for areas like oncology and immunology represents a significant growth opportunity with higher margins.

Risk Factors

Faces intense competition from larger, well-capitalized life science tools companies and risks technological disruption from next-generation proteomics methods.
The costly and uncertain regulatory pathway for diagnostic approval also poses a challenge to clinical market entry.

Competitive Landscape

RayBiotech competes in the crowded life science research tools market against giants like Bio-Techne (R&D Systems), Abcam, and Thermo Fisher, as well as specialized multiplex assay companies like Luminex (now part of DiaSorin). Its competitive edge relies on its specialized antibody array expertise, broad product portfolio, and customer service.